Menu Close

Category: Daily News

WCIRB Proposes .5% Rate Increase for Next Year

The WCIRB Governing Committee voted to authorize the WCIRB to submit a January 1, 2018 Advisory Pure Premium Rate Filing to the California Insurance Commissioner.

The Filing will propose advisory pure premium rates that average $2.01 per $100 of payroll, which is 14.3% less than the industry average filed pure premium rate of $2.34 as of July 1, 2017, and 0.5% more than the average approved July 1, 2017 advisory pure premium rate of $2.00. This modest proposed increase follows five consecutive advisory pure premium rate decreases since early 2015 that have totaled more than 27%.

In his presentation to the Governing Committee, WCIRB EVP and Chief Actuary Dave Bellusci noted that the indicated January 1, 2018 average advisory pure premium rate, while slightly above the average approved July 1, 2017 pure premium rate, is more than 7% below the average January 1, 2017 advisory pure premium rate. Mr. Bellusci identified some of the factors contributing to this reduction over the last year:

– Medical losses have continued to develop downward
– Claim settlement rates have continued to accelerate
– Increasing loss adjustment expense trends have moderated
– Increased wage growth is being forecast

Mr. Bellusci also noted that countering these favorable trends and contributing to this modest proposed increase from the average approved July 1, 2017 advisory pure premium rates are recently rising average claim severities and continued sharp growth in the volume of cumulative injuries.

The WCIRB will submit its January 1, 2018 Pure Premium Rate Filing to the California Department of Insurance (CDI) on or around August 18, 2017.

The CDI will schedule a public hearing to consider the Filing and once the Notice of Proposed Action and Notice of Public Hearing is issued, the WCIRB will post a copy in the Filings and Plans section of the WCIRB website.

Court Limits Exclusive Remedy Protection for Co-workers

Melony Light began working as a seasonal Park Aide at the California Department of Parks and Recreations’s Ocotillo Wells District in San Diego County in 2010. In 2011 she was promoted to a permanent position as an Office Assistant.

Kathy Dolinar was the Superintendent of the Ocotillo Wells District and Leda Seals’s supervisor. Seals and Dolinar were close friends.

In fall 2011, Seals recommended Light for an “out-of-class” assignment as an Office Technician. An “out-of-class” assignment is a temporary assignment to a position in a higher classification with an accompanying increase in pay. Before the end of that assignment, in approximately February 2012, Seals recommended Light for a second out-of-class assignment as a Management Services Technician.

Melony Light was friends with a coworker, Delane Hurley. Seals believed Hurley to be a lesbian. Seals repeatedly made comments to Light intended to make her uncomfortable about her friendship with Hurley, to enlist Light in Seals’s harassment of Hurley based on her sexual orientation, and to encourage Light to cease all contact with Hurley. Seals’s actions allegedly caused Light to suffer emotional distress.

Hurley eventually took medical leave for stress. While she was absent, Seals asked Light to go through Hurley’s workspace and remove any personal items. Light objected because she did not feel comfortable going through Hurley’s things, but Seals insisted. Seals also told Light to move into Hurley’s office because Hurley would not be coming back to the District. Light again objected, but Seals told her the move was nonnegotiable. This situation escalated ultimately involving Kathy Dolinar as Superintendent and a convoluted series of related events.

Ultimately Light filed civil litigation against the Department for retaliation, disability discrimination, and failure to prevent retaliation and discrimination, all in violation of the Fair Employment and Housing Act. The trial court ruled in favor of the Recreation Department, and her former supervisors, defendants Leda Seals and Kathy Dolinar, following orders granting defendants’ motions for summary judgment. The Court of Appeal reversed in the partially published case of Light v Calif. Dept. of Parks and Recreation.

As to Seals and Dolinar, the court concluded contrary to the trial court that workers’ compensation exclusivity does not bar Light’s claim for intentional infliction of emotional distress under the circumstances here. As to the Department, the court concluded that triable issues of material fact preclude summary adjudication of Light’s retaliation claim, but not her disability discrimination claim.

“[T]he exclusive remedy provisions are not applicable under various circumstances, sometimes various identified as ‘conduct where the employer or insurer stepped out of their proper roles’ [citations], or ‘conduct of an employer having a “questionable” relationship to the employment’ [citations], but which may be essentially defined as not stemming from a risk reasonably encompassed within the compensation bargain.”

“Because our discussion of the interplay between workers’ compensation exclusivity and intentional infliction of emotional distress addresses an important legal issue, and our interpretation differs from a recent opinion by our colleagues in Division Three of this court (Yau v. Santa Margarita Ford, Inc. (2014) 229 Cal.App.4th 144) , we will publish that discussion, as well as our discussion of the FEHA retaliation claim on which it relies.”

Yau interpreted the California Supreme Court’s 2008 opinion in Miklosy v. Regents of the University of Cal. (2008) 44 Cal.4th 876, 902 to allow only a single exception to the workers’ compensation exclusivity rule and concluded,that the “exception does not, however, allow a ‘distinct cause of action, not dependent upon the violation of an express statute or violation of a fundamental public policy.’ ” (Ibid., quoting Miklosy, supra 44 Cal.4th at p. 902.).

“We believe Yau reads Miklosy too narrowly……..In sum, absent further guidance from our Supreme Court, we are unwilling to abandon the longstanding view that unlawful discrimination and retaliation in violation of FEHA falls outside the compensation bargain and therefore claims of intentional infliction of emotional distress based on such discrimination and retaliation are not subject to workers’ compensation exclusivity.”

CVS Faces “Fraudulent” Clawback Pricing Class Action

A California woman is suing CVS, the largest pharmacy chain in America, for allegedly charging more to customers who use insurance to pay for certain generic prescriptions. The lawsuit seeks class-action status.

NBC News reports that the lawsuit, filed on Monday, accuses CVS Health Corporation of participating in a “fraudulent scheme” and claims the plaintiff, Megan Schultz, paid $165.68 for a prescription in July that, had she bought without using insurance, would have only cost $92.

“CVS never told her that paying in cash would allow her to pay 45% less for the drug; instead, CVS remained silent and took her money – knowing full well that no reasonable consumer would make such a choice,” the complaint says.

The problem, it alleges, is with co-pays sent back to pharmacy benefit managers, or PBMs – the intermediary between insurance companies and pharmacies who negotiate the prices that insurance companies have to pay the pharmacies. PBMs control which pharmacies are in-network for the insurers, incentivizing CVS to offer them a portion of their sales so they can get more clients.

But consumers picking up prescriptions at their neighborhood CVS are blind to that. The agreements between CVS and the PBMs are based on confidential contracts, meaning the “consumer pays the amount negotiated between the PBM and CVS even if that amount exceeds the price of the drug without insurance,” the suit says.

As a result, it continues, CVS can overcharge unknowing costumers by collecting co-pays that exceed the pharmacists’ price and then remit the excess payment back to the PBMs in what’s known as “clawback” payments.

CVS denied the allegations, responding in a statement that they “are built on a false premise and are completely without merit.”

The pharmacy chain said.”Co-pays for prescription medications are determined by a patient’s prescription coverage plan, not by the pharmacy. Pharmacies collect the co-pays that are set by the coverage plans. Our pharmacists work hard to help patients obtain the lowest out-of-pocket cost available for their prescriptions. Also, our PBM CVS Caremark does not engage in the practice of co-pay clawbacks. CVS has not overcharged patients for prescription co-pays, and we will vigorously defend against these baseless allegations.”

David Balto, a former policy director of the Federal Trade Commission who is now an antitrust lawyer, called the alleged conduct by CVS “egregious” and told NBC News that PBMs are in dire need of federal regulation. “No market is as thinly regulated as PBMs, and they’re increasingly taking advantage of it,” he said. “I think it’s crystal clear: Letting tthese entities live in a Wild West regulatory environment just leads to higher costs for consumers.”

But the particular problem of clawbacks has only recently gotten attention, mostly at the state level. Last month, Connecticut Gov. Dan Malloy signed a bill to stop the practice.

The complaint says a least 16 other lawsuits have been filed against various drugstore chains accused of engaging in clawback practices.

FBI Probes Orange County Addiction Center Empire

Sovereign Health is a mental health and addiction provider with a footprint throughout Southern California, several states and India. Tonmoy Sharma is its chief executive.

Sharma started Sovereign the year after he lost his license in the UK. He was a psychiatrist in the UK, until his license was revoked for conduct deemed dishonest, unprofessional and misleading, according to documents from the General Medical Council of the UK, which licenses physicians there. There is no record that he holds a license as a physician in California.

One center with six beds grew to 17 centers with 743 beds. A giant map hanging on the conference room wall details another 851 beds in development across the nation, which would bring the total to 1,594 beds.

Last year, his company sued Health Net , one of the nation’s largest insurers, for failing to pay $55 million for medical services rendered by Sovereign-related companies. Sovereign Health’s claims were routinely denied, according to the Los Angeles Superior Court complaint. In 2015, only 36 percent of Sovereign Health’s claims were paid. In 2016 only 3 percent of its claims were paid.

In a counter-suit Health Net argued that Sharma and his companies are engaged in massive fraud that harms all consumers. Sovereign-related companies – and many other addiction-treatment providers – “have abused the Affordable Care Act in a manner that threatens the ongoing viability of health insurers,” Health Net’s suit said. “This scheme, which involves fraudulently obtaining insurance policies and the submission of thousands of false and fraudulent claims, also raises the costs of healthcare coverage to consumers, who ultimately will have to pay higher insurance premiums.”

Sovereign and its affiliates comprise one of the largest groups of fraudulent providers, Health Net charged. Within the span of a single year, Sovereign’s companies went from billing Health Net less than $50,000 a month to more than $13 million a month, Health Net’s counter-suit said. How can that happen? Many clinics – including Sovereign’s – “have been engaged in a sophisticated fraud involving paying kick-backs to ‘buy’ hundreds of patients from teams of brokers, or ‘cappers,’ who find the patients in 12-step programs, AA meetings, homeless shelters and jails, often from outside California, and then ‘sell’ them for cash to the highest-bidding clinic,” its suit said.

What Health Net describes echoes a recent investigation of the industry by the Southern California News Group. Though many legitimate centers remain, critics and long-time insiders say a darker version of the industry is emerging, built around an illicit world of patient recruiters, fraud-driven clinics and drug-testing mills. Southern California, where the implementation of Obamacare makes it easy for recent arrivals to sign on for insurance, is on the front line of the conflict.

This summer federal and state agents raided several locations of Sovereign Health as part of an ongoing probe. No arrests were made when officials executed search warrants at sites in Culver City, Palm Desert, San Clemente and San Juan Capistrano. The search warrants were filed under seal, and officials were barred from discussing the extent of the investigation.

Litigation and FBI probes are not the least of Sharma’s worries. The article in the Orange County Register also reports that “body brokers” from other providers are in his parking lots trying to steal away his patients – and their insurance coverage ‘ every day.

Hospital Pays $10M for Stem Cell Research Fraud

Medical care in workers’ compensation is based upon evidence based research. Sadly, some of this evidence is nothing more than the results of fraud.

Brigham and Women’s Hospital in Boston and its parent health care system, Partners HealthCare System, have agreed to pay $10 million in a bid to resolve the allegations that a stem cell research lab at BWH attracted and received federal grant money by fraudulent means.

Former lab scientist Piero Anversa and his colleagues Annarosa Leri and Jan Kajstura allegedly used manipulated and fabricated data to get approval for grant applications that were submitted to the U.S. National Institutes of Health.

The U.S. Attorney’s Office for the District of Massachusetts which revealed the settlement said that the controversial laboratory work involved a study concerning the potentials of the human heart in repairing itself. Unfortunately, other scientists were not able to replicate the results of the study, which was published in the journal Circulation in September 2012.

The American Heart Association, which publishes the journal Circulation, issued a retraction for the 2012 paper on the human heart’s regenerative powers prompted by reviews of BWH and the Harvard Medical School, which determined the data were compromised enough to warrant a retraction.

In a statement, the U.S. Attorney’s Office said that BWH itself shared to the government allegations against Anversa’s lab disclosing its concerns to the Office of the Inspector General, Office of Research Integrity, and the U.S. Department of Health and Human Services and worked with the Department of Justice. It also commended the effort of the hospital in disclosing the allegations.

“Medical research fraud not only wastes scarce government resources but also undermines the scientific process and the search for better treatments for serious diseases,” said acting U.S. Attorney William Weinreb. “We commend Brigham and Women’s for self-disclosing the allegations of fraudulent research at the Anversa laboratory, and for taking steps to prevent future recurrences of such conduct.”

The hospital has been conducting its own investigation since at least 2014 albeit no finding has yet been released.

“BWH is committed to ensuring that research conducted at the institution is done under the most rigorous scientific standards and has made significant enhancements to research integrity compliance protocols as a result of this event,” the hospital said.

The government alleges that among the problematic works in the laboratory included invalid and inaccurately characterized heart stem cells, improper protocols, misleading or reckless record-keeping and discrepancies of data and images that were submitted in applications to the NIH research grants and publications.

The government said that at the direction of Anversa and the two other researchers, the laboratory included scientific data in claims to NIH in a bid to get funds from NIH. The research into how and if it is possible for stem cells to be used for treating heart diseases has attracted millions of dollars in federal funding. Brigham said that the lab received a total of $42 million from NIH awards.

The three researchers are no longer affiliated with BWH and the laboratory closed in 2015.

DWC Proposes ACOEM Modifications to MTUS

The Department of Industrial Relations’ Division of Workers’ Compensation has issued a notice of public hearing which will take place on September 6, 2017 for proposed evidence-based updates to the Medical Treatment Utilization Schedule (MTUS) regulations by Administrative Director order.

There have been many new scientific and medical developments since the MTUS was initially adopted in 2007. Because most of the treatment guidelines have not been updated since 2007, these new scientific and medical developments have not been incorporated into the MTUS. The MTUS must be able to keep up with the evolving nature of scientific evidence to ensure that its recommendations accurately represent current standards of care. Thus, the primary policy objective of this action is to update the MTUS’ medical treatment guidelines so that its recommendations accurately represent current evidence-based standards of care.

These proposed evidence-based updates to the MTUS incorporate by reference the American College of Occupational and Environmental Medicine’s (ACOEM’s) most recent treatment guidelines to the General Approaches, Clinical Topics, and Special Topics sections of the MTUS.Below is a list of the most recent ACOEM guidelines that will be incorporated by reference into the MTUS:

Initial Approaches to Treatment Guideline (ACOEM June 30, 2017)
Cervical and Thoracic Spine Disorders Guideline (ACOEM May 27, 2016)
Shoulder Disorders Guideline (ACOEM August 1, 2016)
Elbow Disorders Guideline (ACOEM 2013)
Hand, Wrist, and Forearm Disorders Guideline (ACOEM June 30, 2016)
Low Back Disorders Guideline (ACOEM February 24, 2016)
Knee Disorders Guideline (ACOEM October 28, 2015)
Ankle and Foot Disorders Guideline (ACOEM September 2015)
Eye Disorders Guideline (ACOEM April 1, 2017)
Hip and Groin Guideline (ACOEM May 1, 2011)
Occupational/Work-Related Asthma Medical Treatment Guideline (ACOEM January 4, 2016)
Occupational Interstitial Lung Disease Guideline (ACOEM January 4, 2016)
Chronic Pain Guideline (ACOEM May 15, 2017)
Opioids Guideline (ACOEM April 20, 2017)

The public hearing is scheduled for September 6, 2017 at 10:00 a.m. in the auditorium of the Elihu Harris Building, 1515 Clay Street, Oakland, California. Members of the public may review and comment on the proposed evidence-based updates to the MTUS until 5 p.m. on September 6, 2017.

These proposed evidence-based updates to the MTUS regulations are exempt from Labor Code sections 5307.3 and 5307.4 and the rulemaking provisions of the Administrative Procedure Act. However, DWC is required to have a 30-day public comment period, hold a public hearing, respond to all the comments received during the public comment period, and publish the order online.

WC Sector Improved “Significantly” Since 2011

A recent report from Moody’s Investors Service shows that the U.S. workers’ compensation sector has improved significantly since 2011 as the domestic economy and labor market have gradually recovered and insurers achieved cumulative rate increases.

However, competition is increasing and profitability, while good, is diminishing.

Further margin compression is likely over the next two years, according to the report, which noted that the WC sector’s fortunes are closely tied to the U.S. labor market, given the compulsory nature of the benefits the insurance provides. The falling national unemployment rate, 4.4% as of June 2017 from near 10% several years ago, is positive for the sector.

And if you were wondering about how much significance the WC sector has, Moody’s report notes that WC is the largest single commercial line for US P&C insurers, comprising nearly 19% of U.S. commercial lines premium volume and approximately 10% of the P&C industry’s total direct premiums written, behind only personal automobile and homeowners insurance.

Responding to questions posed by PropertyCasualty, Sid Ghosh, vice president and senior analyst for Moody’s, based in New York, said that “one general observation is that the claims frequency trend has been flat to slightly negative in WC for a long time even as the economy has added a significant number of jobs in the last couple of years”.

“With improvements in workplace safety, we expect frequency trend for our rated insurers to remain slightly negative, in line with their longer-term track record. In addition, with medical cost trends in the mid-single digit range, we expect overall loss cost trends to remain low unless there is an uptick in lawyer involvement or medical inflation.”

“Although we can’t comment on what a risk manager should or should not do with regard to maintaining and controlling costs, we can say that the role of a risk manager in an insurance organization is governed by its enterprise risk management (ERM) principles and guidelines”.

“Most well-diversified national WC writers adhere to strict risk controls standards set forth by their ERM standards and guidelines. The complexity of assessing risks would depend on an insurer’s exposure profile and geographic diversification.”

Drobot, Sobol Face August Lien Hearings

Senate Bill (SB) 1160 and Assembly Bill (AB) 1244 introduced new changes to the workers’ compensation system for adjudicating liens.

Following a criminal conviction that provides a disposition order that the liens will be dismissed, those liens in which the convicted medical provider has an ownership interest will be automatically dismissed in the Workers’ Compensation system by operation of law.

Where the criminal case disposition is silent regarding the outstanding liens, the DWC Administrative Director will identify all liens owned, in whole or in part, by the convicted medical provider and will schedule a consolidated proceeding at a venue designated by the Chief Judge.

According to Labor Code Section 139.21(g), it will be presumed that the liens of the convicted medical provider were based on services connected to the fraud which resulted in the criminal conviction. The statute specifically requires that the medical provider affirmatively prove by a preponderance of the evidence that the services were not connected to the fraud.

Even assuming that the medical provider is able to overcome this hurdle, the employer will retain its ability to defeat the lien on all existing grounds, such as that the services were not reasonably designed to effectuate cure or relief of an industrial injury, that the services were not reasonably calculated to offer proof in connection with a contested issue or that the charges exceeded the Official Medical Fee Schedule or the Medical-Legal Fee Schedule.

The industry will now be given an opportunity to see how this new law works. Pending lien consolidation hearings for suspended physicians, practitioners or providers are posted on the DWC Website. The DWC has scheduled lien consolidation status conferences in August for suspended providers Philip A. Sobol, Michael R. Drobot and Michael D. Drobot on August 16, 17 and 23 respectively. All three will be heard in Van Nuys before WCJ William Gunn.

Combined, the three have roughly 13,000 liens, which have been consolidated pursuant to the chief judge’s order, in the workers’ compensation system pending further determination, according to the DWC.  The list of lien claims for Philip A. Sobol, is 322 pages, Michael R. Drobot is 183 pages, and Michael D. Drobot is 74 pages long.  The documents reflect the case number, injured worker, employer and claims administrator.  

Although LC 139.21(h) provides that “The special lien proceedings shall be governed by the same laws, regulations, and procedures that govern all other matters before the appeals board,” it is not yet clear if any of the employers will have due process rights to call witnesses and present evidence at the consolidated lien hearings, rights to discovery, or more importantly, if employers do not participate if they will be limited in presenting defenses at hearings on each individual case.

Michael D. Drobot, former CEO and owner of Pacific Hospital of Long Beach, pled guilty for his role in a scheme to illegally refer patients for spinal surgeries. DWC suspended him from participating in the California workers’ compensation system on April 28.

Michael R. Drobot operated California Pharmacy Management and Industrial Pharmacy Management, companies that also participated in the kickback scheme. The son of Michael D. Drobot, he pled guilty in U.S. District Court last year to conspiracy and illegal kickback charges and was suspended May 15.

Philip Sobol, an orthopedic surgeon in Los Angeles, was suspended in May based on a criminal conviction involving fraud and abuse of the workers’ compensation system. Sobol pled guilty for participating in the kickback scheme at Pacific Hospital of Long Beach, illegally referring thousands of his patients for spinal surgeries.

DEA Proposes 20% Reduction in Opiate Manufacturing

The Drug Enforcement Administration (DEA) has proposed a reduction of opiate medications that may be manufactured in the U.S. next year by 20 percent as compared to 2017. The proposed notice was published in the Federal Register on August 7, 2017 and available for public inspection today.

The DEA has proposed to reduce more commonly prescribed schedule II opioid painkillers, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, codeine, meperidine and fentanyl. Demand for these opioid medicines has dropped, according to sales data obtained by DEA from IMS Health, a company that provides insurance companies with data on prescriptions written and prescription medications sold in America.

The Proposed Aggregate Production Quotas (APQ) for Schedule I and II controlled substances that is being published in the Federal Register reflects the total amount of controlled substances needed to meet the country’s legitimate medical, scientific, research, industrial, and export needs for the year and for the maintenance of reserve stocks.

When Congress passed the Controlled Substances Act, the quota system was intended to reduce or eliminate diversion from “legitimate channels of trade” by controlling the quantities of the basic ingredients needed for the manufacture of controlled substances. The purpose of quotas is to provide for an adequate and uninterrupted supply for legitimate medical need of schedule I and schedule II controlled substances, which have a high potential for abuse, while limiting the amounts available to prevent diversion.

DEA must balance the production of what is needed for legitimate use against the production of an excessive amount of these potentially harmful substances. DEA establishes an APQ for more than 250 schedule I and II controlled substances annually.

In setting the APQ, DEA considers data from many sources, including estimates of the legitimate medical need from the Food and Drug Administration; estimates of retail consumption based on prescriptions dispensed; manufacturers’ disposition history and forecasts; data from DEA’s own internal system for tracking controlled substance transactions; and past quota histories.

Once the aggregate quota is set, DEA allocates individual manufacturing and procurement quotas to those manufacturers that apply for them. DEA may revise a company’s quota at any time during the year if change is warranted due to increased sales or exports; new manufacturers entering the market; new product development; or product recalls.

Members of the public can comment on the proposal over the next 30 days.

12 Arrested as 7 Sham LA Medical Clinics Closed

The operators of seven sham Southern California “pop-up” medical clinics were among 12 defendants taken into custody this week on federal drug trafficking charges that allege they diverted at least 2 million prescription pills – including oxycodone and other addictive and dangerous narcotics – to the black market.

Two indictments returned by a federal grand jury alleges that members of the conspiracy profited from illicit prescriptions that were issued without any legitimate medical purpose through a series of clinics that periodically opened and closed in a “nomadic” style.

Those arrested include Minas Matosyan, an Encino man also known as “Maserati Mike,” who is charged with leading the scheme. He owned six of the seven sham clinics, which were, at times, located in the Westlake District, North Hollywood and the city of Orange.

The indictments and search warrants describe how Matosyan would “rent out recruited doctors to sham clinics.” Matosyan allegedly supplied corrupt doctors in exchange for kickbacks derived from proceeds generated when the other sham clinics created fraudulent prescriptions or submitted fraudulent bills to health care programs.

In one example described in the court documents, Matosyan provided a corrupt doctor to a clinic owner in exchange for $120,000. When the clinic failed to pay the money and suggested instead that Matosyan “take back” the corrupt doctor, Matosyan demanded his money and said, “Doctors are like underwear to me. I don’t take back used things.”

The conspirators also allegedly stole the identities of doctors who refused to participate in the scheme. In an intercepted telephone conversation described in court documents, Matosyan offered a doctor a deal to “sit home making $20,000 a month doing nothing.” When the doctor refused the offer, the conspirators nevertheless created prescription pads in the doctor’s name and allegedly began selling fraudulent prescriptions for oxycodone without the doctor’s knowledge or consent.

The indictment also charges Matosyan and others – including Glendale-based criminal defense attorney Fred Minassian – with obstruction of justice for allegedly creating fraudulent medical records in an effort to deter the investigation. After a load of Vicodin was seized from one of the conspiracy’s major customers, Matosyan allegedly oversaw the creation of fake medical paperwork in an effort to make it appear the drugs had been legitimately prescribed. The indictment describes intercepted conversations in which Minassian strategized on how to deceive law enforcement, which included a plan to bribe a doctor to lie to authorities.

The 12 defendants arrested are:

– Minas Matosyan, 36, of Encino, who is accused of leading the scheme by recruiting corrupt doctors, overseeing the theft of other doctors’ identities, and negotiating the sale of fraudulent prescriptions and narcotic pills;
– Armen Simonyan, 52, of Burbank, who allegedly managed the operations at some of the fraudulent clinics;
– Grisha Sayadyan, 66, of Burbank, who allegedly managed the operations at various clinics and sold oxycodone and Vicodin pills directly to black market customers;
– Sabrina Guberman, 45, of Encino, who, while working at the sham clinics, allegedly lied to pharmacies seeking to verify the fraudulent narcotic prescriptions, which included creating and sending fake medical paperwork;
– Frederick Manning Jr., 47, of Santa Ana, allegedly one of the major drug customers of the clinics, who is charged with agreeing to purchase as many as 1,000 pills per week of narcotics from Matosyan;
– Fred Minassian, 50, of Glendale, the criminal defense attorney who allegedly spearheaded the scheme to lie to law enforcement by making it falsely appear that Vicodin seized from Freddie Manning Jr. had been legitimately prescribed by a doctor;
– Ralph Manning, 49, of North Hills (no relation to Frederick Manning Jr.), who is charged with being one of the principal couriers Matosyan used to deliver fraudulent prescriptions and “bulk quantities” of narcotic pills;
– Hayk Matosyan, 30, of Granada Hills, Matosyan’s brother, who allegedly filled fraudulent narcotic prescriptions at pharmacies and sold the resulting narcotics pills to black-market customers.
– Marisa Montenegro, 54, of West Hills, who allegedly filled fraudulent prescriptions;
– Elizabeth Gurumdzhyan, 25, of Hollywood, who allegedly filled fraudulent prescriptions;
– Anait Guyumzhyan, 27, of Hollywood, who allegedly filled prescriptions for oxycodone and returned the drugs to Matosyan-operated clinics in exchange for cash payment; and
– James Wilson, 54, of Venice, who alone is charged in the second indictment with illegally selling oxycodone prescriptions out of a Long Beach clinic that he controlled.

Authorities are continuing to seek two defendants named in the main indictment. Those fugitives are: Gary Henderson, 62, of Lancaster, who allegedly purchased fraudulent oxycodone prescriptions from Matosyan; and an unidentified conspirator known only by the name “Cindy.”